Suppression of β‐catenin signaling in HCC may improve antitumor T-cell activation, resulting in the production of CD8+ effector T cells, promoting their penetration into the TME, and reducing CD8+ T-cell exhaustion after an initial response to anti‐PD‐1 treatment (33). The gene discussed is CD8A; the disease is hepatocellular carcinoma.